Vera J. Suman - Concepedia

Author

Vera J. Suman

Also Known As

Brink, Amy, Dockter, Travis J., Esserman, Laura J., He, Y, Klee, Eric W, Ratain, Mark J., Suman, Vera J., V J Suman, V SUMAN, V Suman

477

Publications

29.2K

Citations

H-Index

235

Concepts

All Affiliations

Mayo Clinic Mayo Clinic in Arizona Mayo Clinic in Florida WinnMed The University of Texas MD Anderson Cancer Center

About

Vera J. Suman is an author at Mayo Clinic specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	45	92	7.3K
2	Health Sciences	19	23	2.3K
3	Engineering	4	4	452
4	Nursing	3	3	254
5	Arts	1	1	35

Vera J. Suman

214

Publications

27.4K

Citations

H-Index

Page 1

	Year	Citations
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer Edward H. Romond, Edith A. Perez, John Bryant, New England Journal of Medicine	2005	5.3K
Whole-genome analysis informs breast cancer response to aromatase inhibition Matthew J. Ellis, Li Ding, Dong Shen, Nature	2012	1K
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831 Edith A. Perez, Edward H. Romond, Vera J. Suman, Journal of Clinical Oncology	2014	984
Benign Breast Disease and the Risk of Breast Cancer Lynn C. Hartmann, Thomas A. Sellers, Marlene H. Frost, New England Journal of Medicine	2005	929
Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes Matthew P. Goetz, James M. Rae, Vera J. Suman, Journal of Clinical Oncology	2005	778
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31 Edith A. Perez, Edward H. Romond, Vera J. Suman, Journal of Clinical Oncology	2011	712
Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials Edward L. Korn, Ping-Yu Liu, Sandra J. Lee, Journal of Clinical Oncology	2008	695
Meningioma Grading Arie Perry, Scott L. Stafford, B. W. Scheithauer, The American Journal of Surgical Pathology Neuro-oncologyHistologic Brain InvasionTumoral PathologyHistologic GradingMedicine	1997	623
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031 Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Journal of Clinical Oncology	2011	554
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen Matthew P. Goetz, Stacey K. Knox, Vera J. Suman, Breast Cancer Research and Treatment Endocrine-related CancerMedicineGynecologyAdjuvant TamoxifenBreast Cancer	2006	550

Page 1